April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
24-hour diurnal intraocular pressure (IOP) evaluation in eyes with POAG or ocular hypertension treated with unoprostone isopropyl as measured in both the sitting and supine position
Author Affiliations & Notes
  • Alan L Robin
    Ophthalmology & Intl Health, Johns Hopkins Univ, Baltimore, MD
  • Ryuji Ueno
    Sucampo Pharmaceuticals, Inc., Bethesda, MD
    Sucampo AG, Zug, Switzerland
  • Footnotes
    Commercial Relationships Alan Robin, Aerie Pharmaceuticals (C), Aerie Pharmaceuticals (I), Allergan, Inc. (C), Aravind Eye Foundation (C), Cipla Pharmaceuticals (C), Glaukos Corporation (C), Merck & Co, Inc (C), Sucampo Pharma Americas, LLC (C); Ryuji Ueno, Sucampo Pharmaceuticals, Inc (E), Sucampo Pharmaceuticals, Inc (I)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 551. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Alan L Robin, Ryuji Ueno; 24-hour diurnal intraocular pressure (IOP) evaluation in eyes with POAG or ocular hypertension treated with unoprostone isopropyl as measured in both the sitting and supine position. Invest. Ophthalmol. Vis. Sci. 2014;55(13):551.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

To assess the 24-hour IOP lowering effect of unoprostone isopropyl ophthalmic solution (UIOS) 0.15% dosed BID.

 
Methods
 

We enrolled 10 subjects with either POAG or ocular hypertension who had untreated IOPs ≥ 23 mm Hg and <32 mm Hg in at least one eye. Technicians administered one drop of UIOS 0.15% at 6 am and 10 pm daily for three days. While the patient was in the sitting position, IOP was measured using Goldmann tonometry; at the same time points, a Perkins tonometer was used to measure IOP with the patient supine. We measured IOP in both the supine and seated positions at Baseline and on Day 3 at the following time points: 0.75, 2, 4, 6, 10, 14, 18, and 22 hours after the 6 am dose.

 
Results
 

The mean age of the subjects was 70.5 years. On Day 3, the mean change in 24-hour diurnal IOP from Baseline in the sitting position was 4.7±1.0 mm Hg (p<0.001). Overall, after three days of BID dosing, IOP reduction measured in the sitting position appears uniform and relatively flat over 24-hours. Mean change in nighttime IOP, assessed in the sitting position after the second daily-dose, is also statistically significantly lower post-treatment versus baseline (p<0.001). On Day 3, the mean change in 24-hour diurnal IOP from Baseline in the supine position was 4.2±0.8 mm Hg (p<0.001). Overall, after three days of dosing twice daily, IOP reduction measured in the supine position appears relatively flat over 24-hours. Mean change in nighttime IOP, assessed in the supine position after the second daily-dose, is also statistically significantly lower post-treatment versus baseline (p<0.001).

 
Conclusions
 

In this study, after three days of dosing, the 24-hour IOP curves of patients treated with unoprostone isopropyl 0.15% ophthalmic solution appear to be relatively flat and suggest around the clock efficacy with BID dosing. The IOP reduction was greater during the day than at night.

     
Keywords: 568 intraocular pressure • 633 outflow: trabecular meshwork  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×